Extendicare Inc.

TSX:EXE.TO

Medical - Care Facilities

Healthcare
$28.81 +2.61%

+$0.86 today

Market cap
$2.74B
Beta
1.16
P/E (TTM)
26.4
EPS (TTM)
$1.28
Dividend yield
1.51%
52W Low $12.12High $35.62

Volume 0.86M

Average 0.34M

Returns on capital

Extendicare Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

25.9%

avg 41.3%

ROIC

13.6%

avg 7.8%

ROA

9.1%

avg 6.7%

Analysis

ROE is currently the strongest return metric at 25.9% versus its period average of 41.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Michael R. Guerriere

Chief Executive Officer, President & DirectorCAD 1.6M61——

David E. Bacon

Executive Vice President & Chief Financial OfficerCAD 861.49K———

John Toffoletto

Senior Vice President, Chief Legal Officer & Corporate SecretaryCAD 800.24K———

Steve Paraskevopoulos

Senior Vice President of ParaMed & Chief Technology OfficerCAD 695.43K———

Matthew Morgan

Chief Medical OfficerCAD 574.7K———

Katie LeMoyne

Senior Vice President & Chief Human Resources OfficerCAD 520.06K———

Jillian E. Fountain

Vice President of Investor RelationsCAD 291.52K———

Joe Belinsky

Vice President of Information Technology & Chief Information Officer————

Kathryn Bradley

Senior Vice President of Corporate Development————

Danielle Labossiere Parr

Vice President of Public Affairs————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/A+9.3%
+16.5% (3yr)3 analysts
RevenueN/AN/A+10.8%
+17.4% (3yr)5 analysts
Net IncomeN/AN/A+11.6%
+16.4% (3yr)5 analysts
EBITN/AN/A+87.5%
+24.7% (3yr)5 analysts

Analysis

Recent growth has been strongest in EBIT at +87.5% over three years. Forward estimates point to EBIT at +24.7% (3yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Extendicare Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about EXE.TO's management, answered from reported figures.

Who manages EXE.TO?

Extendicare Inc. (EXE.TO) lists 10 active executives. The top listed executive is Matthew Morgan, Chief Medical Officer.